Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis
about
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancerConcepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapiesTumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyImmune Checkpoint in Glioblastoma: Promising and ChallengingA randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancerHuman cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell TherapyMonocytic myeloid-derived suppressor cells from females, but not males, alleviate CVB3-induced myocarditis by increasing regulatory and CD4(+)IL-10(+) T cells.IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis.Adoptive Cellular Therapy (ACT) for Cancer Treatment.Myeloid-derived suppressor cells as effectors of immune suppression in cancer.Functio Laesa: Cancer Inflammation and Therapeutic Resistance.Unleashing the immune response against childhood solid cancers.c-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma.Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation.Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.Saying no to drugs: fasting protects hematopoietic stem cells from chemotherapy and aging.Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.Optimized Animal Model of Cyclophosphamide-induced Bone Marrow Suppression.The renaissance of anti-neoplastic immunity from tumor cell demise.Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
P2860
Q26752838-42B97666-AF47-4DBD-AB18-0F907011256EQ26781215-CF8F7DD6-C8CA-48D8-A0DA-CD5780961C88Q26862220-573341BF-E763-4EAE-8254-6F797F474027Q28076473-01CEFC40-7795-4FCD-B991-4A6DE158D5FFQ33650058-82E84ABE-4559-4EF0-9A2F-9F387491E819Q33738937-3501F8EA-51CD-4D4B-9E5A-43E407BE864CQ34809019-42D489DA-DFD1-47E5-9449-438DEF9ACBF5Q35071850-F8A03BEC-AD9B-4C02-AB11-764B53B9D63EQ35863346-B4CFF730-3C75-4FB6-BAFD-B07A3774B4D3Q36173500-4C05F1EA-4D9C-476F-9266-C79196EBBD52Q36651216-CA22B13A-54D3-4FF2-BB33-9C2668FB2BD7Q37078985-73422840-EE20-4FB2-81BF-1EC73AB64F47Q37722551-B6657D5F-1ABB-49AD-8A71-6267B1B10506Q38381929-932AF677-3DDB-4368-958B-2365D310F01BQ38525024-9DA42F33-247F-4154-883C-E3B1A0EA8D88Q38636155-53B849CA-CAA0-42C1-B98C-6EEABE846A81Q38848219-A8C8C1B4-AF7A-4214-83A2-202D0DF3DC7FQ38864758-59206BCE-A4A6-4F8C-936D-EDA3D7D36462Q39172861-DBA104CF-9622-4647-BB3F-137E3AC47AF6Q39224315-AAB98E2C-0510-46FA-8FDB-BD335A40190CQ41644238-6D819E04-7F0D-4D57-985F-8B8EC78CD428Q42177586-4BD60B4E-1802-411A-B133-A3C4627BA1FCQ42288675-97943778-2B9A-4CEB-B0C4-501E8BF7D88DQ43083956-321578F8-614F-4D0C-AD4F-8B44F9A2C008Q46129475-8C8CF7FA-CCB4-421A-A631-00BF2C7ACE38Q46540456-BDCDB9E4-855F-44B6-88E1-6F9929EA6D67Q47561666-D2BDFC66-8684-4ACE-A63A-FB7E4E3AE720Q47777535-44CAB09F-00D8-47AE-BA02-44957D3FF3EAQ48193643-1EF951EE-31A7-41C6-9C6E-5C85ABB435B3Q50031768-9A685AF0-E12E-47C2-8469-B8E03E7FE7DAQ52758913-E38C51E0-6557-4A4E-82B5-385E4A8A4330Q55004657-80029750-4A41-4043-83E3-1C77FC2A085A
P2860
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immunosuppressive myeloid cell ...... es through the PD-1-PD-L1 axis
@ast
Immunosuppressive myeloid cell ...... es through the PD-1-PD-L1 axis
@en
type
label
Immunosuppressive myeloid cell ...... es through the PD-1-PD-L1 axis
@ast
Immunosuppressive myeloid cell ...... es through the PD-1-PD-L1 axis
@en
prefLabel
Immunosuppressive myeloid cell ...... es through the PD-1-PD-L1 axis
@ast
Immunosuppressive myeloid cell ...... es through the PD-1-PD-L1 axis
@en
P2093
P2860
P1433
P1476
Immunosuppressive myeloid cell ...... es through the PD-1-PD-L1 axis
@en
P2093
Andrew L Mellor
Antoni Krasinski
Bruce R Blazar
Henrique Lemos
Matthew Walters
Matthias Mack
Phillip Chandler
P2860
P304
P356
10.1158/0008-5472.CAN-13-3596
P407
P577
2014-04-29T00:00:00Z